Company intelligence / Profile preview

XYone Therapeutics

Canton, MA, United Statesxyonetx.com ↗

Ownership: Private
Development stage: Clinical

Overview

XYone is a clinical-stage biopharmaceutical company that has developed novel proprietary ADC drugs targeting MUC1, an oncoprotein overexpressed in over 80% of epithelial cancers. The company has successfully out-licensed two portfolio assets, with one being licensed to Roche/Poseida Therapeutics for CAR technology applications in solid tumors. Their first ADC drug has been selected for the NCI NExT program, with the National Cancer Institute fully funding its development, manufacturing, and FDA approval process without taking equity or commercial rights.[3]

Therapeutic areas: Oncology
Modalities: Antibody drug conjugate (ADC)Bispecific antibodyCAR-T
Industry: Biotech

Drug pipeline

6 assets

XYA02

5 more assets in the full pipeline.

Partnerships

Roche/Poseida TherapeuticsNational Cancer Institute (NCI NExT program)

Beyond the preview

Go deeper on XYone Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYone Therapeutics.